Skip to main content
BioNTech Investor News·DE·

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapy Gotistobart Phase 2 overall survival data in patients with

Read releases like this the second they cross the wire.

1,400+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 72-hour free trial, no card required.

Start the free trial →

Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.

PPN Source →
Shared via PPN World — real-time press release intelligence.
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting · BioNTech Investor News · PPN World